News
ADTX
2.370
+4.41%
0.100
Weekly Report: what happened at ADTX last week (0415-0419)?
Weekly Report · 2d ago
Aditxt, Inc. Annual Report on Form 10-K for the Year Ended December 31, 2023
Press release · 04/17 01:20
Weekly Report: what happened at ADTX last week (0408-0412)?
Weekly Report · 04/15 11:00
Weekly Report: what happened at ADTX last week (0401-0405)?
Weekly Report · 04/08 11:05
Aditxt, Inc. Announces Strategic Acquisition of Appili Therapeutics
TipRanks · 04/04 21:13
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Stryve Foods, Inc. (NASDAQ:SNAX) fell sharply following a fourth-quarter revenue miss. The company posted adjusted loss of $1.90 per share. VivoPower International PLC shares surged 315% to $6.10 after the company announced a merger.
Benzinga · 04/02 17:23
Why Aditxt Stock Is Volatile Today
Aditxt, Inc. Shares are volatile after the company announced it will acquire Appili Therapeutics. Aditxt shares are moving on heavy trading volume following the announcement. The company does not pay a dividend but does have a few ways to return value to shareholders.
Benzinga · 04/02 16:42
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Nexalin Technology (NASDAQ:NXL) stock increased by 47.9% to $2.81 during Tuesday's regular session. MSP Recovery (NASdaq:LIFW) shares moved upwards by 33.26%. Q4 earnings report came out 4 days ago. Losers Acorda Therapeutics and Gritstone Bio.
Benzinga · 04/02 16:31
Canopy Growth, Exact Sciences, Stereotaxis among healthcare movers
Healthcare On the Move: Canopy Growth, Exact Sciences, Stereotaxis among healthcare movers. S&P 500 Health Care Sector -1.52% to 1682.8. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 04/02 14:00
Aditxt to Buy Biopharmaceutical Company Appili Therapeutics for Undisclosed Amount
Aditxt said it will buy Appili Therapeutics for an undisclosed amount. The company is a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. Appili has a diverse portfolio including the U.S. Department of Defense.
Dow Jones · 04/02 12:58
Aditxt signs agreement to acquire Appili Therapeutics
Healthcare M&A Aditxt signs agreement to acquire Appili Therapeutics. ADTX +2.45% premarket to $3.258. The biopharmaceutical company is focused on drug development for infectious diseases and medical countermeasures.
Seeking Alpha · 04/02 12:51
ADITXT SIGNS A DEFINITIVE AGREEMENT TO ACQUIRE APPILI THERAPEUTICS INC., DEVELOPER OF A BIODEFENSE VACCINE FUNDED BY THE U.S. DEPARTMENT OF DEFENSE (DOD)
Reuters · 04/02 12:30
ADITXT INC - UNDER ARRANGEMENT AGREEMENT, ADIVIR AGREED TO ACQUIRE ALL ISSUED AND OUTSTANDING CLASS A COMMON SHARES OF APPILI
Reuters · 04/02 12:30
ADITXT INC - IF TRANSACTION IS COMPLETED, APPILI SHARES WILL BE DELISTED FROM TSX
Reuters · 04/02 12:30
Press Release: Aditxt Signs a Definitive -2-
The Arrangement Agreement contains customary terms and conditions. Appili Therapeutics is a biopharmaceutical company developing treatments for life-threatening infections. Aditxt is an innovation platform dedicated to discovering, developing, and deploying promising innovations. The Company's shares will be listed on the TSX and OTCQX.
Dow Jones · 04/02 12:30
Press Release: Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD) Assets include the FDA-approved LIKMEZ(TM) and the ATI-1701 tularemia vaccine defense program. Aditxt's wholly owned subsidiary, Adivir, will acquire Appili.
Dow Jones · 04/02 12:30
*Aditxt Signs A Definitive Agreement To Acquire Appili Therapeutics Inc., Developer Of A Biodefense Vaccine Funded By The U.S. Department Of Defense (DoD) >ADTX APLI.T
Dow Jones · 04/02 12:30
Aditxt, Through Adivir Subsidiary, To Acquire All Issued And Outstanding Class A Common Shares Of Appili; Appili Shareholders To Receive 0.002745004 Shares Of Aditxt And $0.0467 For Each Appili Share Held, Representing Total Consideration Of ~$0.0561
Under the terms of the Arrangement Agreement, shareholders of Appili will receive 0.002745004 of a share of common stock of Aditxt. Appili shareholders will also receive a cash consideration of approximately US$0.0467 for each Appili Share held. The Transaction Consideration represents a 117% premium to the closing price of the Appili Shares.
Benzinga · 04/02 11:35
APPILI THERAPEUTICS INC - ARRANGEMENT AGREEMENT ALSO PROVIDES FOR PAYMENT OF A TERMINATION FEE OF CDN$1.25 MLN IN CERTAIN CIRCUMSTANCES
Reuters · 04/02 11:30
MSTR, BIOR and ARBK among pre-market losers
MSTR, BIOR and ARBK among pre-market losers. Bitcoin production jumps 24% M/M in March. Mountain Crest Acquisition Corp IV (MCAF) reports fourth quarter and full year 2023 financial results. MSTR, BDRX, LIXT, CLSK, AVTX, ADTX, IINN, MCAF, OCEA, GUTS, GRDI.
Seeking Alpha · 04/01 12:31
More
Webull provides a variety of real-time ADTX stock news. You can receive the latest news about Aditxt Inc through multiple platforms. This information may help you make smarter investment decisions.
About ADTX
Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.